share_log

Is WELL Health a Buy?

Is WELL Health a Buy?

WELL Health值得買入嗎?
The Motley Fool ·  12/24 05:10

WELL Health Technologies (TSX:WELL) is a digital healthcare company focusing on developing technology and services that could aid healthcare professionals in delivering positive patient outcomes. The company has witnessed healthy buying this year, with its stock price rising by 84.4%. Its solid quarterly performances and continued acquisitions have boosted its financials.

WELL健康科技(TSX:WELL)是一家數字醫療公司,專注於開發能夠幫助醫療專業人員實現積極患者結果的技術和服務。該公司今年見證了健康的購買趨勢,股價上漲了84.4%。其穩健的季度業績和持續的收購推動了其財務表現。

Let's assess whether WELL Health offers buying opportunities at these levels by looking at its third-quarter earnings and growth prospects.

讓我們通過查看其第三季度收益和增長前景來評估WELL健康是否在這些水平提供購買機會。

WELL Health's third-quarter performance

WELL健康的第三季度業績

Last month, WELL Health reported an impressive third-quarter performance, with its top line growing by 27% to $251.7 million. Organic growth of 23% and acquisitions over the last four quarters drove its sales, while the divestments offset some of the growth. It had around 1.48 million patient visits and 2.24 patient interactions during the quarter, representing a year-over-year growth of 41% across both metrics. Amid the topline growth, its gross profits grew by 19%. However, its adjusted gross margin contracted by 150 basis points to 44.6% amid increased contributions from lower-margin recruiting revenue from the acquisition of CarePlus.

上個月,WELL健康報告了令人印象深刻的第三季度業績,營業收入增長了27%,達到了$25170萬。23%的有機增長和過去四個季度的收購推動了其銷售,而資產剝離則抵消了一部分增長。該季度大約有148萬的患者訪問和2.24次患者互動,分別代表了這兩個指標的同比增長41%。在營業收入增長中,其毛利增長了19%。然而,因CarePlus收購帶來低毛利招聘收入的增加,其調整後毛利率收縮了150個點子,降至44.6%。

The digital healthcare company's adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) grew 16% to $32.7 million. However, the adjusted EBITDA to WELL's shareholders rose by 10% to $25.1 million. Its adjusted net income stood at $13 million, slightly improving from $12.9 million in the previous year's quarter. The company generated $16.2 million of adjusted free cash flow during the quarter, supported by its comprehensive cost-cutting program, which it implemented earlier this year. Now, let's look at its growth prospects.

這家數字醫療公司的調整後EBITDA(息稅折舊攤銷前利潤)增長了16%,達到了$3270萬。然而,WELL的adjusted EBITDA對股東的收益增長了10%,達到了$2510萬。其調整後的凈利潤爲$1300萬,略有改善,比去年同期的$1290萬有所提升。公司在本季度生成了$1620萬的調整後自由現金流,受益於其在今年早些時候實施的全面成本削減計劃。現在,讓我們來看看它的增長前景。

WELL Health's growth prospects

WELL健康的增長前景

Given their accessibility, cost-effectiveness, and convenience, more people are adopting digital healthcare services. Technological advancements and improving internet penetration have also contributed to the rising popularity of virtual services, thus expanding the addressable market for WELL Health.

鑑於其可獲取性、成本效益和便利性,越來越多的人正在採用數字醫療服務。技術進步和Internet Plus-related滲透率的提高也促進了虛擬服務的日益普及,從而擴大了WELL健康的可尋址市場。

Meanwhile, the company continues to invest in advancing AI (artificial intelligence)-powered tech enablement for care providers, which could strengthen its position in the digital healthcare sector. The company's acquisition pipeline looks solid, with 17 signed LOIs (letters of intent) and definitive agreements. Also, the company's cost-cutting program would continue to improve its profitability.

與此同時,公司繼續投資於推動人工智能(AI)技術賦能護理提供者,這可能會增強其在數字醫療板塊的地位。公司的收購管道看起來穩固,已有17份簽署的意向書(LOI)和最終協議。此外,公司的節省成本計劃將繼續改善其盈利能力。

Moreover, WELL Health has rebranded its subsidiary WELL Provider Solutions Group as WELLSTAR Technologies. This pure-play software-as-a-service (SaaS) technology company offers high-quality technology and services to around 37,000 healthcare providers to improve patient care. The company is also working on spinning out WELLSTAR, thus providing investors with an attractive investment opportunity in healthcare technology SaaS. It expects to complete the spinoff by the end of next year.

此外,WELL Health已將其子公司WELL Provider Solutions Group更名爲WELLSTAR Technologies。這家純軟體即服務(Saas-雲計算)科技公司爲大約37,000家醫療提供者提供高質量的技術和服務,以改善患者護理。該公司還在努力分拆WELLSTAR,從而爲投資者提供醫療科技Saas領域的有吸引力的投資機會。預計在明年年底之前完成分拆。

WELLSTAR recently acquired two healthcare-focused technology companies, which could contribute $15 million in annualized revenue, thus raising its 2025 pro forma revenue to $70 million. Also, its gross margins could remain above 80% while its EBITDA margin would be around 20%. Considering all these factors, I believe WELL Health's growth prospects look healthy.

WELLSTAR最近收購了兩家專注於醫療的科技公司,這可能會爲其帶來1500萬的年度營業收入,從而將其2025年的預估營業收入提升至7000萬。此外,其毛利率可能保持在80%以上,而其EBITDA毛利率將約爲20%。考慮到所有這些因素,我認爲WELL Health的增長前景良好。

Investors' takeaway

投資者的看法

Despite the substantial increase in its stock price, WELL Health's valuation looks attractive. Its next-12-month price-to-sales and NTM price-to-earnings multiples stand at 1.6 and 24.2, respectively. Given its solid growth prospects, improving profitability, and attractive valuation, I expect WELL Health to deliver superior returns over the next three years.

儘管其股價大幅上漲,但WELL Health的估值看起來依然有吸引力。其未來12個月的市銷率和未來市盈率分別爲1.6和24.2。考慮到其穩固的增長前景、改善的盈利能力和有吸引力的估值,我預計WELL Health在未來三年將提供超額回報。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論